{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:53:11Z","timestamp":1793771591359,"version":"4.6.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jconrel.2024.11.057","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T14:09:26Z","timestamp":1733321366000},"page":"756-766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["RNA therapies for musculoskeletal conditions"],"prefix":"10.1016","volume":"377","author":[{"given":"Chiara","family":"Mancino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Sontam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mcculloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Corbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Taraballi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10267","key":"10.1016\/j.jconrel.2024.11.057_bb0005","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0140-6736(20)32340-0","article-title":"Global estimates of the need for rehabilitation based on the global burden of disease study 2019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Cieza","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jconrel.2024.11.057_bb0010","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/jox14030072","article-title":"Lubricant strategies in osteoarthritis treatment: transitioning from natural lubricants to drug delivery particles with lubricant properties","volume":"14","author":"Fragassi","year":"2024","journal-title":"J. Xenobiot."},{"issue":"12","key":"10.1016\/j.jconrel.2024.11.057_bb0015","doi-asserted-by":"crossref","first-page":"10386","DOI":"10.3390\/ijms241210386","article-title":"Reasons for the sex bias in osteoarthritis research: a review of preclinical studies","volume":"24","author":"Franke","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41413-020-00112-2","article-title":"Arthritis and the role of endogenous glucocorticoids","volume":"8","author":"Macfarlane","year":"2020","journal-title":"Bone Res."},{"issue":"12","key":"10.1016\/j.jconrel.2024.11.057_bb0025","doi-asserted-by":"crossref","first-page":"2100152","DOI":"10.1002\/adtp.202100152","article-title":"Nanodelivery systems face challenges and limitations in bone diseases management","volume":"4","author":"Giordano","year":"2021","journal-title":"Adv. Therapeut."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.901317","article-title":"Gene therapy in Orthopaedics: Progress and challenges in pre-clinical development and translation","volume":"10","author":"Watson-Levings","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0040","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s12889-021-10953-z","article-title":"Prevalence, burden of disease, and lost in health state utilities attributable to chronic musculoskeletal disorders and pain in Chile","volume":"21","author":"Zitko","year":"2021","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12916-021-01905-w","article-title":"Pattern and trend of five major musculoskeletal disorders in China from 1990 to 2017: findings from the global burden of disease study 2017","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0050","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.addr.2006.01.007","article-title":"Oral treatment options for degenerative joint disease\u2014presence and future","volume":"58","author":"Steinmeyer","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.addr.2006.01.011","article-title":"Pathophysiology and treatment of pain in joint disease","volume":"58","author":"Schaible","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2024.11.057_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/jsp2.1033","article-title":"Osteoarthritis and intervertebral disc degeneration: quite different, quite similar","volume":"1","author":"Rustenburg","year":"2018","journal-title":"JOR Spine"},{"issue":"6","key":"10.1016\/j.jconrel.2024.11.057_bb0065","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0070","first-page":"413","article-title":"Adherence to methotrexate therapy in rheumatoid arthritis","volume":"32","author":"Arshad","year":"2016","journal-title":"Pak. J. Med. Sci."},{"issue":"10136","key":"10.1016\/j.jconrel.2024.11.057_bb0075","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jconrel.2024.11.057_bb0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41584-021-00625-y","article-title":"Ankylosing spondylitis: an autoimmune or autoinflammatory disease?","volume":"17","author":"Mauro","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"9","key":"10.1016\/j.jconrel.2024.11.057_bb0085","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.3390\/jcm10091880","article-title":"Autoinflammatory features in gouty arthritis","volume":"10","author":"Galozzi","year":"2021","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0090","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s13018-022-03222-1","article-title":"Global prevalence of falls in the older adults: a comprehensive systematic review and meta-analysis","volume":"17","author":"Salari","year":"2022","journal-title":"J. Orthop. Surg. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0095","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.molonc.2012.02.009","article-title":"Omics and therapy\u2013a basis for precision medicine","volume":"6","author":"Garay","year":"2012","journal-title":"Mol. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2024.11.057_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ocarto.2021.100144","article-title":"The future of deep phenotyping in osteoarthritis: how can high throughput omics technologies advance our understanding of the cellular and molecular taxonomy of the disease?","volume":"3","author":"Mobasheri","year":"2021","journal-title":"Osteoarthritis Cartilage Open"},{"issue":"4","key":"10.1016\/j.jconrel.2024.11.057_bb0105","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1302\/0301-620X.101B4.BJJ-2019-0013.R1","article-title":"Cell therapy in orthopaedics: where are we in 2019?","volume":"101","author":"Rodeo","year":"2019","journal-title":"Bone Joint J."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-016-1178-8","article-title":"Extracellular vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis","volume":"18","author":"Withrow","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrrheum.2013.159","article-title":"Progress in intra-articular therapy","volume":"10","author":"Evans","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.11.057_bb0120","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.fertnstert.2018.05.006","article-title":"Personalized medicine: motivation, challenges, and progress","volume":"109","author":"Goetz","year":"2018","journal-title":"Fertil. Steril."},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.31138\/mjr.29.2.67","article-title":"The involvement of MicroRNAs in osteoarthritis and recent developments: a narrative review","volume":"29","author":"Panagopoulos","year":"2018","journal-title":"Mediterr. J. Rheumatol."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0130","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2474-10-148","article-title":"Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes","volume":"10","author":"Tardif","year":"2009","journal-title":"BMC Musculoskelet. Disord."},{"issue":"5","key":"10.1016\/j.jconrel.2024.11.057_bb0135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00011-012-0438-6","article-title":"MiRNA-140 is a negative feedback regulator of MMP-13 in IL-1beta-stimulated human articular chondrocyte C28\/I2 cells","volume":"61","author":"Liang","year":"2012","journal-title":"Inflamm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13075-016-0997-y","article-title":"E2 regulates MMP-13 via targeting miR-140 in IL-1beta-induced extracellular matrix degradation in human chondrocytes","volume":"18","author":"Liang","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.jconrel.2024.11.057_bb0145","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/rheumatology\/keq247","article-title":"Silencing microRNA-34a inhibits chondrocyte apoptosis in a rat osteoarthritis model in vitro","volume":"49","author":"Abouheif","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3892\/ijmm.2016.2618","article-title":"MicroRNA-34a affects chondrocyte apoptosis and proliferation by targeting the SIRT1\/p53 signaling pathway during the pathogenesis of osteoarthritis","volume":"38","author":"Yan","year":"2016","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2024.11.057_bb0155","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ymthe.2016.12.020","article-title":"Intra-articular delivery of Antago-miR-483-5p inhibits osteoarthritis by modulating Matrilin 3 and tissue inhibitor of metalloproteinase 2","volume":"25","author":"Wang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0160","doi-asserted-by":"crossref","first-page":"18743","DOI":"10.1038\/srep18743","article-title":"Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment","volume":"6","author":"Aini","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.jconrel.2024.11.057_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091785","article-title":"Anti-inflammatory therapy for temporomandibular joint osteoarthritis using mRNA medicine encoding Interleukin-1 receptor antagonist","volume":"14","author":"Deng","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0170","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/14653249.2011.629645","article-title":"Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients","volume":"14","author":"Ha","year":"2012","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/humc.2017.249","article-title":"A multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients","volume":"29","author":"Kim","year":"2018","journal-title":"Hum. Gene. Ther. Clin. Dev."},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0038-1676803","article-title":"Results of a phase II study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-beta1","volume":"33","author":"Lee","year":"2020","journal-title":"J. Knee Surg."},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0185","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jcp.24727","article-title":"Runx1 activities in superficial zone chondrocytes, osteoarthritic chondrocyte clones and response to mechanical loading","volume":"230","author":"LeBlanc","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0190","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bioactmat.2024.05.020","article-title":"\u03b2-Catenin mRNA encapsulated in SM-102 lipid nanoparticles enhances bone formation in a murine tibia fracture repair model","volume":"39","author":"Nelson","year":"2024","journal-title":"Bioactive Mater."},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0195","article-title":"New treatment for osteoarthritis: gene therapy. Precis","volume":"6","author":"Li","year":"2023","journal-title":"Clin. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/BOR.0000000000000918","article-title":"Osteoarthritis gene therapy in 2022","volume":"35","author":"Evans","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0205","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s12891-017-1830-8","article-title":"Structural effects of intra-articular TGF-beta1 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial","volume":"18","author":"Guermazi","year":"2017","journal-title":"BMC Musculoskelet. Disord."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8010009","article-title":"Emerging concepts and challenges in rheumatoid arthritis gene therapy","volume":"8","author":"Deviatkin","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2024.11.057_bb0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejpb.2023.10.010","article-title":"Overcoming delivery barriers for RNA therapeutics in the treatment of rheumatoid arthritis","volume":"192","author":"Zhang","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"10","key":"10.1016\/j.jconrel.2024.11.057_bb0220","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1089\/hum.2006.17.1027","article-title":"Synthetic messenger RNA as a tool for gene therapy","volume":"17","author":"Rabinovich","year":"2006","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/vaccines9010065","article-title":"Nanomaterial delivery systems for mRNA vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2024.11.057_bb0230","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.smim.2017.08.015","article-title":"Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-an innate immune system standpoint","volume":"34","author":"Granot","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2020.107534","article-title":"The challenge and prospect of mRNA therapeutics landscape","volume":"40","author":"Weng","year":"2020","journal-title":"Biotechnol. Adv."},{"issue":"10","key":"10.1016\/j.jconrel.2024.11.057_bb0240","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1021\/acs.biomac.9b00999","article-title":"Polymeric carriers for nucleic acid delivery: current designs and future directions","volume":"20","author":"Peng","year":"2019","journal-title":"Biomacromolecules"},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0245","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.mcna.2019.10.007","article-title":"Osteoarthritis: pathology, diagnosis, and treatment options","volume":"104","author":"Abramoff","year":"2020","journal-title":"Med. Clin. North Am."},{"issue":"11","key":"10.1016\/j.jconrel.2024.11.057_bb0250","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mayocp.2013.04.027","article-title":"Advances in regenerative orthopedics","volume":"88","author":"Evans","year":"2013","journal-title":"Mayo Clin. Proc."},{"issue":"11","key":"10.1016\/j.jconrel.2024.11.057_bb0255","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2024.11.057_bb0260","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/17425247.2023.2185220","article-title":"Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases","volume":"20","author":"Carneiro","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2024.11.057_bb0265","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0270","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Control. Release"},{"issue":"7607","key":"10.1016\/j.jconrel.2024.11.057_bb0275","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.11.057_bb0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: current perspectives","volume":"154","author":"Samaridou","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.jconrel.2024.11.057_bb0285","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2024.11.057_bb0290","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0005-2736(01)00399-6","article-title":"Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes","volume":"1558","author":"Song","year":"2002","journal-title":"Biochimica et Biophysica Acta (BBA)-Biomembranes"},{"issue":"6","key":"10.1016\/j.jconrel.2024.11.057_bb0300","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"13","key":"10.1016\/j.jconrel.2024.11.057_bb0310","doi-asserted-by":"crossref","first-page":"15832","DOI":"10.1021\/acsami.3c18830","article-title":"Harnessing RNA technology to advance therapeutic vaccine antigens against chagas disease","volume":"16","author":"Mancino","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"10","key":"10.1016\/j.jconrel.2024.11.057_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105127","article-title":"Freeze-drying for the preservation of immunoengineering products","volume":"25","author":"Kommineni","year":"2022","journal-title":"iScience"},{"issue":"11","key":"10.1016\/j.jconrel.2024.11.057_bb0320","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41551-018-0284-0","article-title":"Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA","volume":"2","author":"Islam","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"3","key":"10.1016\/j.jconrel.2024.11.057_bb0325","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41596-021-00665-4","article-title":"Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages","volume":"17","author":"Huang","year":"2022","journal-title":"Nat. Protoc."},{"issue":"553","key":"10.1016\/j.jconrel.2024.11.057_bb0330","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1063","article-title":"siRNA nanoparticles targeting CaMKII\u03b3 in lesional macrophages improve atherosclerotic plaque stability in mice","volume":"12","author":"Tao","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"25","key":"10.1016\/j.jconrel.2024.11.057_bb0335","doi-asserted-by":"crossref","first-page":"7779","DOI":"10.1073\/pnas.1505629112","article-title":"Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment","volume":"112","author":"Zhu","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2024.11.057_bb0340","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112696119","article-title":"Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer","volume":"119","author":"Kong","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120966","article-title":"Systemic delivery of mRNA and DNA to the lung using polymer-lipid nanoparticles","volume":"275","author":"Kaczmarek","year":"2021","journal-title":"Biomaterials"},{"issue":"599","key":"10.1016\/j.jconrel.2024.11.057_bb0350","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0355","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41467-022-28279-8","article-title":"Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy","volume":"13","author":"Xiao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0360","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejpb.2023.05.010","article-title":"Microfluidic mixing as platform technology for production of chitosan nanoparticles loaded with different macromolecules","volume":"188","author":"Greco","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"18","key":"10.1016\/j.jconrel.2024.11.057_bb0365","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1021\/ja034429c","article-title":"Parallel synthesis and biophysical characterization of a degradable polymer library for gene delivery","volume":"125","author":"Akinc","year":"2003","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.jconrel.2024.11.057_bb0370","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/ar7002336","article-title":"A combinatorial polymer library approach yields insight into nonviral gene delivery","volume":"41","author":"Green","year":"2008","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abk2855","article-title":"High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA","volume":"8","author":"Rui","year":"2022","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.jconrel.2024.11.057_bb0380","doi-asserted-by":"crossref","first-page":"1805116","DOI":"10.1002\/adma.201805116","article-title":"Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium","volume":"31","author":"Patel","year":"2019","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0385","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"issue":"26","key":"10.1016\/j.jconrel.2024.11.057_bb0390","doi-asserted-by":"crossref","first-page":"E5859","DOI":"10.1073\/pnas.1805358115","article-title":"Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters","volume":"115","author":"McKinlay","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2024.11.057_bb0395","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/acscentsci.1c00361","article-title":"An mRNA SARS-CoV-2 vaccine employing charge-altering releasable transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory","volume":"7","author":"Haabeth","year":"2021","journal-title":"ACS Cent. Sci."},{"issue":"39","key":"10.1016\/j.jconrel.2024.11.057_bb0400","doi-asserted-by":"crossref","first-page":"E9153","DOI":"10.1073\/pnas.1810002115","article-title":"mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice","volume":"115","author":"Haabeth","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2024.11.057_bb0405","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1021\/acsomega.7b00367","article-title":"pH and thermal dual-responsive nanoparticles for controlled drug delivery with high loading content","volume":"2","author":"Zheng","year":"2017","journal-title":"ACS Omega"},{"issue":"49","key":"10.1016\/j.jconrel.2024.11.057_bb0410","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202005029","article-title":"Light: a magical tool for controlled drug delivery","volume":"30","author":"Tao","year":"2020","journal-title":"Adv. Funct. Mater."},{"issue":"6","key":"10.1016\/j.jconrel.2024.11.057_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e16640","article-title":"Immunomodulatory biomimetic nanoparticles target articular cartilage trauma after systemic administration","volume":"9","author":"Mancino","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0420","first-page":"GE01","article-title":"Non viral vectors in gene therapy- an overview","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2024.11.057_bb0425","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4155\/tde.12.128","article-title":"Recent developments and perspectives on gene therapy using synthetic vectors","volume":"4","author":"Schlenk","year":"2013","journal-title":"Ther. Deliv."},{"issue":"8","key":"10.1016\/j.jconrel.2024.11.057_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/genes13081370","article-title":"Appraisal for the potential of viral and nonviral vectors in gene therapy: A Review","volume":"13","author":"Butt","year":"2022","journal-title":"Genes (Basel)"},{"issue":"5","key":"10.1016\/j.jconrel.2024.11.057_bb0435","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.trechm.2022.02.002","article-title":"Emerging biomimetic nanotechnology in orthopedic diseases: progress, challenges, and opportunities","volume":"4","author":"Zhang","year":"2022","journal-title":"Trends Chem."},{"key":"10.1016\/j.jconrel.2024.11.057_bb0440","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924008162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924008162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T21:29:40Z","timestamp":1734643780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924008162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":88,"alternative-id":["S0168365924008162"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.057","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA therapies for musculoskeletal conditions","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}